ASTX727 Low Dose in Lower Risk Myelodysplastic Syndromes (MDS)

Phase 2, randomised, open-label trial of inqovi in myelodysplastic syndrome (MDS) (3 arms), sponsored by Taiho Oncology. Primary endpoints: Incidence of drug-related Grade >=3 Adverse Events (AEs) or dose-limiting toxicities (DLTs) and Hematologic response based on normalization of conversion of any baseline cytopenia or anemia. Started Jul 2018; status: completed.